Regimen Reference Order – BRST – trastuzumab Adjuvant every 21 days

Planned Course: **Every 21 days for 1 year (18 doses)**
Indication for Use: **Breast Cancer Adjuvant**

CVAD: At Provider's Discretion

Blood work at provider's discretion: not required for treatment

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – BRST – trastuzumab Adjuvant every 21 days

Establish primary solution 500 mL of: normal saline

Drug	Dose	CCMB Administration Guideline
Cycle 1		
trastuzumab	8 mg/kg Loading Dose	IV in normal saline 250 mL over 90 minutes
Cycles 2 to 18		
trastuzumab	6 mg/kg	IV in normal saline 250 mL over 30 minutes

Flush after each medication:

- 50 mL over 6 minutes (500 mL/hr)

In the event of an infusion-related hypersensitivity reaction, refer to the '**Hypersensitivity Reaction Standing Order'**

REQUIRED MONITORING

All Cycles

- Left Ventricular Ejection Fraction (LVEF) monitoring is recommended at baseline and every 4 cycles

Cycle 1 Only

- Full vital signs (temperature, heart rate, respiration, blood pressure and O_2 saturation) at baseline and as clinically indicated
- Observe for 1 hour post-infusion
- Full vital signs prior to discharge

Cycles 2 and 3

- Full vital signs at baseline and as clinically indicated
- Observe for 30 minutes post-infusion
- Full vital signs prior to discharge

Cycle 4 Onwards

- Full vital signs at baseline and as clinically indicated
- Monitor as needed

DISCHARGE INSTRUCTIONS

- N/A

ADDITIONAL INFORMATION

- Reassess dose with clinically significant weight changes (for orders with a one year duration)